Stock Insiders is a podcast series focussed on investing, hosted by TV presenter and news journalist Christina Morrissy. 

In this episode Christina chats to Sam Watson, CEO at Bioxyne Limited (ASX:BXN).

Bioxyne recently announced it hit a $1 million annualised revenue run rate in May 2023 for its trademarked Dr Watson brand sales to Amazon in the UK.

Bioxyne’s acquisition of Breathe Life Sciences is paying off with its well-established Dr Watson brand of cannabis products continuing to be a consumer favourite.

To hear about Bioxyne’s acquisition of Breathe Life Sciences and more.

Click below

On mobile? Click here to listen with Apple podcasts, here for Spotify.

Like to tune in through another app? Just search for Stock Insiders with Christina Morrissy and subscribe!

Read MoreCannabisDrug DevelopmentHealth

Featured Companies

You might be interested in